Major depressive disorder (MDD) is a disabling mental disorder with a complicated etiology that involves the interplay of genetic and environmental factors. In addition to the core symptoms of low mood, loss of interest, hopelessness, fatigue, difficulty concentrating, and suicidal ideation or behavior, many patients also have cognitive impairment, moderate to severe anxiety, and other psychological symptoms. Concurrent mental disorders ('dual diagnosis') or serious physical conditions are also commonly seen in individuals with depression. Thus, clinical cases of depression are highly heterogeneous. [@B1]

Currently, the most commonly employed psychiatric treatment of MDD is antidepressant medication, which may or may not be supplemented with some form of psychotherapy. However, research over the last decade has indicated that for many patients with MDD one medication is not enough to address the broad range of symptoms they experience as part of their depressive episode. One major problem in selecting an antidepressant for a patient is that all currently available antidepressants must be administered at the full dose for 2 to 4 weeks to determine whether or not they will be effective. Moreover, remission is only seen for 42 to 46% of individuals with MDD administered the full course of an antidepressant at the full dose, and approximately 30% of MDD patients will not remit even after going through separate courses of treatment with multiple antidepressants. [@B2]

One option for dealing with this problem is to administer multiple antidepressants with different mechanisms of action (i.e., 'antidepressant polypharmacy') to simultaneously address the different types of symptoms experienced by the patient and, thus, optimize the treatment effect. [@B3] However, this approach is notrecommended in the practice guidelines of most countries [@B1], [@B3] which typically recommend the use of a single antidepressant for first-episode depression. There are currently few high-quality studies that assess the effectiveness of antidepressant polypharmacy, and the studies that are available are inconsistent. Legitimate concerns about drug-drug interactions that could reduce the treatment effect or increase the prevalence and severity of side-effects - especially among elderly patients - are other reasons clinicians are reluctant to prescribe multiple antidepressants. Due to these considerations, antidepressant polypharmacy is only recommended for patients with treatmentresistant depression who may benefit from the synergistic effect of employing medications that have different mechanisms of action. This rationale based on pharmacological augmentation is highlighted in the recommendations of the American Psychiatry Association's Practice guideline for the treatment of patients with major depressive disorder. [@B4]

The earliest evaluation of antidepressant polypharmacy was conducted by Maes and colleagues who compared the effectiveness of monotherapy fluoxetine versus polypharmacy of fluoxetine with either the 5-HT1Areceptor antagonists pindolol or the 5-HT 2A/2C and a2 -adrenergic receptor antagonists mianserin in the treatment of 31 patients with treatmentresistant depression; they found better outcomes in the two polypharmacy groups than in the fluoxetine monotherapy group.[@B5] Another study by Nelson and colleagues [@B6] also found that combined treatment with fluoxetine and the NE reuptake inhibitor desipramine was more effective than monotherapy with either of the medications. [@B6] Similarly, a recent study by Blier and colleagues documented greater improvement among patients with depression who received combined treatment with mirtazapine and paroxetine for six weeks compared to that of patients who received either drug alone for six weeks. [@B7] A subsequent study found that three different antidepressant combinations (mirtazapine + fluoxetine, mirtazapine + venlafaxine, and mirtazapine + bupropion) were more effective than monotherapy with fluoxetine. [@B8] However, one large single-blind randomized controlled study (n=665) - the Combining Medications to Enhance Depression Outcomes (CO-MED) study - did not find any significant differences in the outcomes of patients treated with single medications versus those of patients treated with combinations of antidepressants. [@B9]

Clinicians who consider antidepressant polypharmacy are particularly concerned about antidepressant side effects which could, potentially, increase in frequency, severity, and persistence when multiple medications are being used simultaneously. Earlier work has shown the dangers of severe side effects including the serotonin syndrome when combining tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) or exacerbated TCA-related side effects when combining TCAs with selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and fluoxetine (which is due to increased plasma TCA levels that result when SSRIs inhibit enzymes that metabolize TCAs). [@B10] The concurrent administration of newer antidepressants with fewer (and milder) side effects may result in a decreased risk of adverse reactions compared to those that occur when combining TCAs and MAOIs of TCAs and SSRIs, but more research is needed to confirm this.

In clinical practice, psychiatrists usually start with one antidepressant. If there is no benefit or the side effects are severe the clinician will change the treatment to another antidepressant. If there is partial benefit and the side effects are relatively mild there are three potential options: (a) increase the dose of the first medication; (b) change to another medication; or (c) augment the first medication with a second antidepressant with an alternative mechanism of action that should, theoretically, improve the treatment effect without seriously exacerbating the side effects. This latter course is the traditional 'multimodal treatment', [@B11] combining compounds with two independent pharmacological mechanisms that complement each other in terms of treatment effect and tolerance. Most currently available antidepressants are, in one sense, already 'multimodal' because they involve multiple pharmacological pathways. Some of these pathways are not directly related to the treatment of depression (which is why they are considered 'dirty' drugs); activation of these non-therapeutic pathways can result in serious side effects when high dosages of the medication are used (outweighing the therapeutic benefit), so in some cases the use of multiple antidepressants can decreasethe risk of serious side effects because lower dosages of each medication can be employed. For a mental disorder with a complicated etiology like MDD, it is theoretically reasonable to provide combined treatment with two or even three medications with different mechanisms of action. [@B12] Recent clinical evidence has shown that the addition of a 'synergist' (including lithium, atypical antipsychotics, buspirone, and thyroxine) to SSRIs can significantly boost the antidepressant effect of SSRIs; this approach is now considered preferable to increasing the dosage of an antidepressant that is having a sub-optimal effect after being given at full dosage for a sufficient length of time. [@B13]

Antidepressant polypharmacy is another type of multimodal treatment that needs to be compared to the use of a single antidepressant and a synergist; there may be situations in which two different antidepressants result in better outcomes than the use of a single antidepressant and a synergist. It is also possible that different combinations of medications have differential effects on outcomes of interest including: (a) resolution of the core symptoms of depression; (b) rapidity of action; (c) frequency, severity, and persistence of side effects; (d) control of associated (non-depressive) symptoms such as anxiety and cognitive impairment; (e) improvement in social functioning and quality of life; and (f) prevention of relapse. Antidepressant polypharmacy is a potentially important addition to the therapeutic options available for treating treatmentresistant depression, but much more work is needed to clarify the situations in which it will be most useful.
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